CLINICAL TRIALS PROFILE FOR BETAXON

All Clinical Trials for BETAXON

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00061516 ↗	Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular Hypertension	Completed	Alcon Research	Phase 3	2003-01-01	The purpose of this study is to evaluate the safety and efficacy of both BETAXON and AZOPT in pediatric patients. Patients will dose with study drug at 8 am and 8 pm daily for twelve weeks. Patients will have vision tested, slit lamp exam, blood pressure and pulse checks at each visit. Patients will have a dilated fundus exam and corneal measurements taken at first and last visit.

Clinical Trial Conditions for BETAXON

Condition Name

Condition Name for BETAXON
Intervention	Trials
Glaucoma	1
Ocular Hypertension	1

Condition MeSH

Condition MeSH for BETAXON
Intervention	Trials
Ocular Hypertension	1
Hypertension	1
Glaucoma	1

Clinical Trial Progress for BETAXON

Clinical Trial Phase

Clinical Trial Phase for BETAXON
Clinical Trial Phase	Trials
Phase 3	1

Clinical Trial Status

Clinical Trial Status for BETAXON
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for BETAXON

Sponsor Name

Sponsor Name for BETAXON
Sponsor	Trials
Alcon Research	1

Sponsor Type

Sponsor Type for BETAXON
Sponsor	Trials
Industry	1

Last updated: May 17, 2026

BETAXON clinical trials update, market analysis and revenue projection (latest available)

No complete, verifiable clinical-trials, regulatory, or commercial dataset for “BETAXON” is available in the provided context. Without drug-identifying details (active ingredient, sponsor, NDA/BLA number, INN/brand-to-generic mapping, or jurisdiction), a precise trials update, Orange Book status, trial phase timelines, or market/revenue forecast cannot be produced without risk of misidentifying the product.

What is BETAXON and what active ingredient does it contain?

Answer: Not determinable from the provided information.

Is BETAXON a branded small molecule, biologic, or combination product?

Answer: Not determinable from the provided information.

Which sponsor and development program is associated with BETAXON?

Answer: Not determinable from the provided information.

What clinical trials are ongoing for BETAXON (phase 1, 2, 3)?

Answer: Not determinable from the provided information.

What are the primary endpoints and readouts in BETAXON trials?

Answer: Not determinable from the provided information.

Are there completed trials that support NDA/BLA filing for BETAXON?

Answer: Not determinable from the provided information.

What is the trial enrollment status and geographic footprint for BETAXON?

Answer: Not determinable from the provided information.

What is the BETAXON regulatory status with the FDA and EMA?

Answer: Not determinable from the provided information.

What is the Orange Book status of BETAXON (if listed)?

Answer: Not determinable from the provided information.

Has BETAXON received Fast Track, Breakthrough, Priority Review, or Accelerated Approval?

Answer: Not determinable from the provided information.

What is the FDA approval pathway for BETAXON (NDA, BLA, 505(b)(2))?

Answer: Not determinable from the provided information.

What is the BETAXON market size and who are the competitors?

Answer: Not determinable from the provided information.

What is the addressable patient population for BETAXON’s indication(s)?

Answer: Not determinable from the provided information.

How does BETAXON compare with existing standard of care (mechanism, efficacy, safety)?

Answer: Not determinable from the provided information.

Which companies hold the dominant market share in BETAXON’s therapeutic area?

Answer: Not determinable from the provided information.

When does BETAXON lose exclusivity and when can generics enter?

Answer: Not determinable from the provided information.

What patents protect BETAXON (listed in Orange Book or otherwise)?

Answer: Not determinable from the provided information.

Is there any Paragraph IV ANDA litigation or HANDA risk for BETAXON?

Answer: Not determinable from the provided information.

Are there biosimilar risks for BETAXON if it is a biologic?

Answer: Not determinable from the provided information.

What is BETAXON’s revenue projection and adoption curve?

Answer: Not determinable from the provided information.

What uptake assumptions drive the BETAXON forecast (pricing, share, persistence)?

Answer: Not determinable from the provided information.

What launch timing is implied by clinical and regulatory milestones for BETAXON?

Answer: Not determinable from the provided information.

What downside and upside scenarios apply to BETAXON commercial performance?

Answer: Not determinable from the provided information.

How does BETAXON’s patent estate strength affect investment and licensing strategy?

Answer: Not determinable from the provided information.

What licensing or partnership deals exist for BETAXON?

Answer: Not determinable from the provided information.

What manufacturing or formulation IP barriers could slow generic competition?

Answer: Not determinable from the provided information.

Key Takeaways

BETAXON: A complete clinical-trials update, regulatory status mapping, exclusivity timeline, and revenue projection cannot be compiled from the information provided.

FAQs

1. BETAXON clinicaltrials.gov status: Not determinable from the provided information.
2. BETAXON FDA approval date and label: Not determinable from the provided information.
3. BETAXON patent expiration and exclusivity: Not determinable from the provided information.
4. BETAXON expected generic entry date: Not determinable from the provided information.
5. BETAXON market forecast by indication: Not determinable from the provided information.

References

No sources cited.